Clinical trial · Interventional
CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer
KRAS (Kirsten Rat Sarcoma) Mutant CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Locally Advanced and Metastatic PANcreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
With an incidence of more than 11,600 new cases per year in France and an annual number of deaths close to the incidence rate, adenocarcinoma of the pancreas is a public health problem. The aim of this study is to assess the predictive value of response to the 1st line of chemotherapy of mutated KRAS ctDNA (circulating tumor DNA) in unresectable metastatic or locally advanced pancreatic adenocarcinomas.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor DNA | — | UNRESOLVED | — |
| KRAS Mutation-Related Tumors | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Only arm
- description
- Blood samples to analyze ctDNA
- interventionNames
- Diagnostic Test: Blood samples
Primary outcomes (1)
- measure
- Correlation of the ctDNA level to the response to chemotherapy
- timeFrame
- 3 months
- description
- Response to chemotherapy was evaluated with RECIST criteria 1.1 on the first CT scan
Secondary outcomes (2)
- measure
- Overall survival
- timeFrame
- 6 months after last patients inclusion
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Proven pancreatic adenocarcinoma (histology or cytology) * Metastatic or locally advanced unresectable * With thoraco-abdomino-pelvic scanner less than a month old * Chemotherapy treatment regardless of the protocol * Patients benefiting from a Social Security scheme or benefiting through the intermediary of a third party * Informed consent signed by the patient after clear and fair information about the study Exclusion Criteria: * Linguistic or psychological refusal or inability to understand and / or sign the informed consent * History of cancer in the 5 years preceding inclusion * Patient who has already received chemotherapy or radiotherapy for pancreatic cancer. * Immediately resectable tumor
References
Publications (1)
- DERIVEDEvrard C, Ingrand P, Rochelle T, Martel M, Tachon G, Flores N, Randrian V, Ferru A, Haineaux PA, Goujon JM, Karayan-Tapon L, Tougeron D. Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study. Dig Liver Dis. 2023 Nov;55(11):1562-1572. doi: 10.1016/j.dld.2023.03.011. Epub 2023 Jun 10. PMID 37308396